Prior to insurance coverage of multiplex tests in Japan, a systematic review of 33 Japanese studies reported that 45% of samples from patients with NSCLC of adenocarcinoma histology (2069/4619) were positive for EGFR mutation [27]. This evidence concerns the gene EGFR and adenocarcinoma.